Eleanor directs editorial content produced by the Commercial Pharma Insights team (Scrip, Generics Bulletin and In Vivo) in the US and Europe, liaising closely with counterparts in policy and regulatory coverage and in Asia. She oversees and contributes to daily analytical content based on biopharma industry developments and trends, interviewing key experts and industry leaders. Eleanor joined Citelien predecessor Informa in 2000 as companies reporter on Scrip, and has held a number of editorial roles on Pharma Intelligence's pharma and medtech publications. She has interviewed countless industry leaders and specialists, explored business developments and strategy, pipeline trends, policy and regulatory stories, delved into M&A, licensing, partnerships, financing, financial reports, clinical trial updates, market trends and more. She regularly appears on conference panels and in the media to discuss matters relating to the biopharma industry. She has an MA in modern languages from the University of Edinburgh and previously worked as a translator of European business news for the Financial Times.
Latest from Eleanor Malone
More than 30 biopharma executives, investors and industry experts shared their views on the environment for funding and deal-making in the year to come. With a patent cliff looming over big pharma at the same time as technology opens manifold possibilities for new approaches to drug discovery and development, the general view is that 2025 will be a busy year for partnering, with a trend towards earlier-stage deals and milestone-dependent payments.
More than 40 industry executives shared their views on where the biopharma industry stands as it enters the new year. Innovation remains the sector’s driving force, but after two years of capital constraint, due diligence is key.
Keytruda, Ozempic and Dupixent were the three best-selling drugs by global revenues in the third quarter. AbbVie’s long-time cash cow Humira finally exited the top 10, slipping to 16th place.
Keytruda and Ozempic held their positions as the number one and two best-selling drugs in the world in the second quarter, while Eli Lilly’s Mounjaro shot to sixth place.
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.